EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CFTR Functional Rescue and Heterogeneous Clinical Outcomes Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis Carrying the W1282R Variant

Elena Kondratyeva iD, Anna Efremova, Yuliya Melyanovskaya iD, Elena Zhekaite, Maria Sapelnikova, Michael Milovanov, Olga Shchagina iD, Anna Voronkova, Victoria Sherman, Stanislav Krasovsky, Sergey Kutsev, Dmitry Goldshtein

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27198896 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Elena Kondratyeva und 11 weiteren Autor:innen. Beteiligte Einrichtung: Research Centre for Medical Genetics,1 Moskvorechye St., 115552 Moscow, Russia. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Aminophenols, Quinolones. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical response to elexacaftor/tezacaftor/ivacaftor (ETI) in people with cystic fibrosis carrying the rare cystic fibrosis transmembrane conductance regulator (CFTR) variant W1282R has not been well characterized. We retrospectively analyzed 12 people with cystic fibrosis treated with ETI for 3–36 months in addition to ongoing standard CF therapy. Baseline lung function was generally preserved in patients with available spirometry (median percent predicted forced expiratory volume in 1 s (ppFEV1), 110%; interquartile range (IQR), 93–123), limiting the potential for further improvement in ppFEV1; no statistically significant change in ppFEV1 was detected during ETI therapy (p = 0.328). Paired data for ppFEV1, body mass index (BMI), and sweat conductivity were available for 8, 12, and 9 patients, respectively. CFTR function was assessed by intestinal current measurement (ICM; n = 4) and patient-derived intestinal organoids (n = 2). Functional testing demonstrated markedly reduced baseline CFTR activity. In the patient with paired ICM measurements before and during ETI therapy, restoration of CFTR-mediated chloride transport was observed, whereas ETI significantly increased forskolin-induced swelling (FIS) in both patient-derived organoid cultures (p < 0.001 for each culture). BMI did not change significantly during ETI therapy (p = 0.269). Sweat conductivity showed a statistically significant overall reduction (median change, −3 mmol/L; p = 0.031); however, marked reductions were observed in only two of nine patients. Interpretation is limited by the small retrospective cohort and incomplete availability of paired clinical and functional data. These findings indicate that functional responsiveness of W1282R-CFTR to ETI may not be accompanied by consistent improvement across the clinical outcomes assessed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorAminophenolsQuinolonesIndolesBenzodioxolesPyridinesPyrazolesPyrrolidinesPyrrolesHumansFemaleMaleAdultRetrospective StudiesTreatment OutcomeYoung AdultTreatment Effect HeterogeneityDrug CombinationsMutationAdolescentQuinolines

Stichwörter der Autor:innen

CFTRCFTR modulatorsW1282Rcystic fibrosiselexacaftor/tezacaftor/ivacaftorforskolin-induced swellingintestinal current measurementintestinal organoids

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorAminophenolsQuinolonesIndolesBenzodioxolesPyridineselexacaftorCFTR protein, humanPyrazoleselexacaftor, ivacaftor, tezacaftor drug combination

Autor:innen und Institutionen

  • Research Centre for Medical Genetics,1 Moskvorechye St., 115552 Moscow, Russia.
  • Independent Researcher, Moscow 121108, Russia.

ORCID-Profile: Elena Kondratyeva, Yuliya Melyanovskaya, Olga Shchagina

Förderung

  • Russian Science Foundation

Zitieren

APA

Kondratyeva, E., Efremova, A., Melyanovskaya, Y., Zhekaite, E., Sapelnikova, M., Milovanov, M., Shchagina, O., Voronkova, A., Sherman, V., Krasovsky, S., Kutsev, S., & Goldshtein, D. (2026). CFTR Functional Rescue and Heterogeneous Clinical Outcomes Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis Carrying the W1282R Variant. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27198896

Vancouver

Kondratyeva E, Efremova A, Melyanovskaya Y, Zhekaite E, Sapelnikova M, Milovanov M, et al. CFTR Functional Rescue and Heterogeneous Clinical Outcomes Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis Carrying the W1282R Variant. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27198896

BibTeX
@article{Kondratyeva2026,
  author = {Kondratyeva, Elena and Efremova, Anna and Melyanovskaya, Yuliya and Zhekaite, Elena and Sapelnikova, Maria and Milovanov, Michael and Shchagina, Olga and Voronkova, Anna and Sherman, Victoria and Krasovsky, Stanislav and Kutsev, Sergey and Goldshtein, Dmitry},
  title = {CFTR Functional Rescue and Heterogeneous Clinical Outcomes Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis Carrying the W1282R Variant},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27198896}
}
Kostenlos starten →